Xenetic Biosciences, Inc. (XBIO)

HashiCorp Statistics

Total Valuation

XBIO has a market cap or net worth of $4.73 million. The enterprise value is -$293,138.

Market Cap	4.73M
Enterprise Value	-293,138

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

XBIO has 1.54 million shares outstanding. The number of shares has increased by 0.49% in one year.

Current Share Class	1.54M
Shares Outstanding	1.54M
Shares Change (YoY)	+0.49%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	6.89%
Owned by Institutions (%)	7.91%
Float	1.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.92
Forward PS	2.24
PB Ratio	0.97
P/TBV Ratio	0.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.20

Current Ratio	8.20
Quick Ratio	7.73
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -53.16% and return on invested capital (ROIC) is -35.13%.

Return on Equity (ROE)	-53.16%
Return on Assets (ROA)	-31.93%
Return on Invested Capital (ROIC)	-35.13%
Return on Capital Employed (ROCE)	-75.70%
Revenue Per Employee	$1.29M
Profits Per Employee	-$1.83M
Employee Count	2
Asset Turnover	0.34
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.41% in the last 52 weeks. The beta is 2.33, so XBIO's price volatility has been higher than the market average.

Beta (5Y)	2.33
52-Week Price Change	-25.41%
50-Day Moving Average	3.37
200-Day Moving Average	3.59
Relative Strength Index (RSI)	40.39
Average Volume (20 Days)	53,630

Short Selling Information

The latest short interest is 32,752, so 2.12% of the outstanding shares have been sold short.

Short Interest	32,752
Short Previous Month	93,447
Short % of Shares Out	2.12%
Short % of Float	2.77%
Short Ratio (days to cover)	0.17

Income Statement

In the last 12 months, XBIO had revenue of $2.58 million and -$3.67 million in losses. Loss per share was -$2.38.

Revenue	2.58M
Gross Profit	2.58M
Operating Income	-3.88M
Pretax Income	-4.47M
Net Income	-3.67M
EBITDA	n/a
EBIT	-3.88M
Loss Per Share	-$2.38

Balance Sheet

The company has $5.16 million in cash and n/a in debt, giving a net cash position of $5.16 million or $3.35 per share.

Cash & Cash Equivalents	5.16M
Total Debt	n/a
Net Cash	5.16M
Net Cash Per Share	$3.35
Equity (Book Value)	5.12M
Book Value Per Share	3.32
Working Capital	4.81M

Cash Flow

Operating Cash Flow	-2.66M
Capital Expenditures	n/a
Free Cash Flow	-2.66M
FCF Per Share	-$1.72

Margins

Gross margin is 100.00%, with operating and profit margins of -150.17% and -142.03%.

Gross Margin	100.00%
Operating Margin	-150.17%
Pretax Margin	-142.03%
Profit Margin	-142.03%
EBITDA Margin	n/a
EBIT Margin	-150.17%
FCF Margin	n/a

Dividends & Yields

XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.49%
Shareholder Yield	-0.49%
Earnings Yield	-75.32%
FCF Yield	-54.61%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	May 15, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

XBIO has an Altman Z-Score of -43.15 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-43.15
Piotroski F-Score	2